For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but
recent results have shown that they could become a reality. Convincing data generated with …

Biomarkers of neurodegeneration and neuronal injury have the potential to improve
diagnostic accuracy, disease monitoring, prognosis, and measure treatment efficacy …

Abstract Introduction Blood‐based Alzheimer's disease (AD) biomarkers provide
opportunities for community studies and across ethnic groups. We investigated blood …

Multiple sclerosis (MS) is a debilitating autoimmune disorder. Currently, there is a lack of
effective treatment for the progressive form of MS, partly due to insensitive readout for …

Neuronal injury is a universal event that occurs in disease processes that affect both the
central and peripheral nervous systems. A blood biomarker linked to neuronal injury would …

Introduction Blood‐based biomarkers of amyloid pathology and neurodegeneration are
entering clinical use. It is critical to understand what factors affect the levels of these markers …

Introduction Plasma biomarkers will likely revolutionize the diagnostic work‐up of
Alzheimer's disease (AD) globally. Before widespread use, we need to determine if …

The advancing validation and exploitation of CSF and blood neurofilament light chain
protein as a biomarker of neuroaxonal damage has deeply changed the current diagnostic …

Background Serum neurofilament light chain (sNfL) is a biomarker of neuronal damage that
is used not only to monitor disease activity and response to drugs and to prognosticate …

Neurofilament light chain (NfL) is a novel biomarker of neurodegenerative diseases. It is
detectable in the peripheral blood, allowing low-invasive assessment of early signs of …